Department of Clinical and Experimental Medicine, University of Padova-Azienda Ospedaliera di Padova, Padova, Italy.
Artif Organs. 2011 Feb;35(2):E33-9. doi: 10.1111/j.1525-1594.2010.01125.x. Epub 2011 Feb 14.
Cardiovascular disease represents the most common cause for the excess of morbidity and mortality found in end-stage renal disease (ESRD) and has prompted the exploration of multiple approaches to improve outcomes in these patients. Cardiovascular risk factors such as increased oxidative stress (OxSt) and inflammation are found in ESRD patients. A vitamin E-coated dialyzer using polysulfone membranes has been suggested to have positive effects on these factors. This 1-year study evaluated in 25 ESRD patients under chronic dialysis, the effects of a vitamin E-coated membrane (VitabranE ViE) "ex vivo" on mononuclear cells, OxSt, and inflammation-related biochemical and molecular biology markers using a molecular biology approach. p22(phox), heme oxygenase (HO)-1, plasminogen activator inhibitor (PAI)-1 protein level, and phosphorylated extracellular signal-regulated kinase (pERK)1/2 status were evaluated at the beginning of the study, after 6 months and after 12 months by Western blot analysis and oxidized low-density lipoprotein (OxLDL) plasma level by enzyme-linked immunosorbent assay, alongside vascular remodeling assessment as measured by carotid intima-media thickness (IMT) in a subgroup of nine randomly selected patients. p22(phox), PAI-1, OxLDL, and pERK all decreased with VitabranE use, while HO-1 increased. Carotid IMT did not increase. Treatment with VitabranE significantly decreases the expression of proteins and markers relevant to OxSt and inflammation tightly associated with cardiovascular disease, and it appears highly likely that VitabranE use will provide a benefit in terms of cardiovascular protection.
心血管疾病是终末期肾病(ESRD)患者发病率和死亡率过高的最常见原因,促使人们探索多种方法来改善这些患者的预后。ESRD 患者存在多种心血管危险因素,如氧化应激(OxSt)增加和炎症。研究表明,使用聚砜膜包被维生素 E 的透析器对这些因素有积极影响。本为期 1 年的研究纳入了 25 名接受慢性透析的 ESRD 患者,采用分子生物学方法评估了维生素 E 包被膜(VitabranE ViE)“体外”对单核细胞、OxSt 和炎症相关生化及分子生物学标志物的影响。在研究开始时、6 个月和 12 个月时,通过 Western blot 分析评估 p22(phox)、血红素加氧酶(HO)-1、纤溶酶原激活物抑制剂(PAI)-1 蛋白水平和磷酸化细胞外信号调节激酶(pERK)1/2 状态,通过酶联免疫吸附试验评估氧化型低密度脂蛋白(OxLDL)的血浆水平,同时在 9 名随机选择的患者亚组中评估颈动脉内膜中层厚度(IMT)以评估血管重塑。使用 VitabranE 治疗可降低 p22(phox)、PAI-1、OxLDL 和 pERK 的表达,而 HO-1 增加。颈动脉 IMT 没有增加。VitabranE 治疗可显著降低与 OxSt 和炎症密切相关的蛋白和标志物的表达,这些标志物与心血管疾病密切相关,因此,VitabranE 的使用很可能会带来心血管保护方面的益处。